Impact of Reimbursement for Biomarker Testing on Clinical PracticeVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Geoffrey Oxnard and Lauren Ritterhouse deliberate on ways reimbursement issues are impacting clinical practice, particularly CMS’s “14-Day Rule.”
Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.
According to Alexander Bastian, it’s very difficult to determine how to integrate cost into the equation of cancer care. He explains that cost should be considered early on and uses Dr. Zafar’s term of financial toxicity, meaning the burden of cost can be as bad or worse than a physical [ Read More ]